Singapore's Temasek injects investment in genomics business

Together with Yun Feng, it co-led a $75m round of funding.

A report from Bloomberg said Singapore’s state-owned investment firm Temasek Holdings Pte made new investments in contract genomics organisation WuXi NextCODE, which is expanding in China as the country pushes into the emerging field of precision medicine.

Yunfeng Capital and Temasek co-led a $75m Series B round of financing into the company, WuXi NextCODE said in a statement. Other investors included Amgen Ventures, a fund founded by Amgen Inc., and private-equity firm 3W Partners.

Read the rest of the story here.
 

Join Singapore Business Review community
Since you're here...

...there are many ways you can work with us to advertise your company and connect to your customers. Our team can help you dight and create an advertising campaign, in print and digital, on this website and in print magazine.

We can also organize a real life or digital event for you and find thought leader speakers as well as industry leaders, who could be your potential partners, to join the event. We also run some awards programmes which give you an opportunity to be recognized for your achievements during the year and you can join this as a participant or a sponsor.

Let us help you drive your business forward with a good partnership!